Methodological and regulatory aspects of pharmaceutical development of biological products

The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.

Materials and methods. The material for the analysis was taken from the abstract databases of PubMed, Google Scholar and e-library.ru. The search was carried out using publications for the period from 2008 to 2023, the keywords were as follows: “biologicals”, “new drug approval”, “drug authorization”, “drug development”, “biosimilar”, taking into account various spellings.

Results. Over the past 15 years, scientists have been observing revolutionary trends and processes in the field of the drug development, especially biopharmaceuticals. Significant advances have been made in gene, immune and cell therapies, resulting in the approval of such drugs more than doubling over the past ten years. The development of biological drugs includes the identification and testing of molecular targets and requires a deep understanding of the structure and functioning of the polypeptides involved in the development of the effect. The features of these active pharmaceutical substances are a high molecular weight, a complex three-dimensional structure and a high immunogenic potential. Preclinical and clinical studies of biologics have unique challenges. Selecting appropriate animal species, understanding the immunogenicity, and assessing pharmacodynamics and toxicological properties require a multilevel, detailed approach. The article discusses the regulatory framework under which these drugs are registered, summarizing the guidelines provided by international organizations such as the International Council for Harmonization and various national agencies.

Conclusion. The analysis highlights the current advances and prospects in the development of biologics, highlighting their key role in future transformations in the treatment of rare diseases and oncology, approaching the era of personalized medicine. Monitoring the development directions and technological approaches, as well as the commitment to global methodological and regulatory aspects can become a catalyst in the development of the Russian pharmacology.

1. Huayamares SG, Lokugamage MP, Da Silva Sanchez AJ, Dahlman JE. A systematic analysis of biotech startups that went public in the first half of 2021. Current Research in Biotechnology. 2022;4:392–401. DOI: 10.1016/j.crbiot.2022.09.004

2. Frame N, Casasanta M, Ben-Joseph O. The winding journey of biotech capital raising: deciphering the jargon. Trends in Biotechnology. 2023;41(10):1213–5. DOI: 10.1016/j.tibtech.2023.06.011

3. Kohn D.B., Chen Y.Y., Spencer M.J. Successes and challenges in clinical gene therapy. Gene Ther. 2023;30(10–11):738–46. DOI: 10.1038/s41434-023-00390-5

4. Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, Khurana I, Banothu AK, Weiskirchen R, Bharani KK. Gene therapy: Comprehensive overview and therapeutic applications. Life Sci. 2022;294:120375. DOI: 10.1016/j.lfs.2022.120375

5. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(Suppl 2):S87–S97. DOI: 10.3747/co.27.5223

6. Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17–35. DOI: 10.1016/j.immuni.2019.12.011

7. El-Kadiry AE, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. Front Med (Lausanne). 2021;8:756029. DOI: 10.3389/fmed.2021.756029

8. Weth FR, Hoggarth GB, Weth AF, Paterson E, White MPJ, Tan ST, Peng L, Gray C. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer. 2023. DOI: 10.1038/s41416-023-02502-9

9. Spellicy SE, Hess DC. Recycled Translation: Repurposing Drugs for Stroke. Transl Stroke Res. 2022;13(6):866–80. DOI: 10.1007/s12975-022-01000-z

10. Kurkin DV, Morkovin EI, Bakulin DA, Gorbunova YuV, Kolosov YuA, Dzhavakhyan MA, Makarenko IE, Drai RV, Zaborovsky AV, Shatalova OV, Strygin AV, Petrov VI, Pleten AP, Prokopov AA, Tatarenko-Kozmina TYu. Overview of drugs approved by the FDA in 2022. Pharmacy & Pharmacology. 2023;11(3):193–210. DOI: 10.19163/2307-9266-2023-11-3-193-210

11. Mello MM. Barriers to Ensuring Access to Affordable Prescription Drugs. Annu Rev Pharmacol Toxicol. 2020;60:275–89. DOI: 10.1146/annurev-pharmtox-010919-023518

12. Zimmermann BM, Eichinger J, Baumgartner MR. A systematic review of moral reasons on orphan drug reimbursement. Orphanet J Rare Dis. 2021;16(1):292. DOI: 10.1186/s13023-021-01925-y

13. Althobaiti H, Seoane-Vazquez E, Brown LM, Fleming ML, Rodriguez-Monguio R. Disentangling the Cost of Orphan Drugs Marketed in the United States. Healthcare (Basel). 2023;11(4):558. DOI: 10.3390/healthcare11040558

14. Paolini Sguazzi G, Muto V, Tartaglia M, Bertini E, Compagnucci C. Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases. Int J Mol Sci. 2021;22(24):13674. DOI: 10.3390/ijms222413674

15. Chavez M., Chen X., Finn P.B., Qi L.S. Advances in CRISPR therapeutics. Nat Rev Nephrol. 2023;19(1):9–22. DOI: 10.1038/s41581-022-00636-2

16. Niyazov RR, Dranitsyna MA, Vasiliev AN, Gavrishina EV. Biosimilars: reproduction of the clinical profile using modern biotechnology. Remedium. 2021;(2):8–24. DOI: 10.21518/1561-5936-2021-2-8-24. Russian

17. Yuan S, Shen DD, Jia R, Sun JS, Song J, Liu HM. New drug approvals for 2022: Synthesis and clinical applications. Med Res Rev. 2023;43(6):2352–91. DOI: 10.1002/med.21976

18. Chia CSB. A Patent review on FDA-approved antibody-drug conjugates, their linkers and drug payloads. ChemMedChem. 2022;17(11):e202200032. DOI: 10.1002/cmdc.202200032

19. Gurgula O. Strategic patenting by pharmaceutical companies - should competition law intervene? IIC Int Rev Ind Prop Copyr Law. 2020;51(9):1062–85. DOI: 10.1007/s40319-020-00985-0

20. Orlova AI. Patent strategies in pharmaceuticals: “patent greening.” Journal of the Intellectual Property Court. 2019;(26):83–9. Russian

21. Martins AC, Albericio F, de la Torre BG. FDA Approvals of Biologics in 2022. Biomedicines. 2023;11(5):1434. DOI: 10.3390/biomedicines11051434

22. Mullard A. 2023 FDA approvals. Nature Reviews Drug Discovery. 2024. DOI: 10.1038/d41573-024-00001-x

23. Sharma K, Sharma KK, Sharma A, Jain R. Peptide-based drug discovery: Current status and recent advances. Drug Discov Today. 2023;28(2):103464. DOI: 10.1016/j.drudis.2022.103464

24. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem. 2020;12(10):939–47. DOI: 10.4155/fmc-2019-0307

25. Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Hum Vaccin Immunother.2021;17(12):5255–68. DOI: 10.1080/21645515.2021.1977057

26. Alamgir ANM. Bioactive compounds and pharmaceutical excipients derived from animals, marine organisms, microorganisms, minerals, synthesized compounds, and pharmaceutical drugs. therapeutic use of medicinal plants and their extracts: volume 2. 2018:311–406. DOI: 10.1007/978-3-319-92387-1_4

27. Bellinvia S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. Expert Opin Drug Discov. 2020;15(11):1283–9. DOI: 10.1080/17460441.2020.1796627

28. Motika SE, Hergenrother PJ. Re-engineering natural products to engage new biological targets. Nat Prod Rep. 2020;37(11):1395–403. DOI: 10.1039/d0np00059k

29. David F, Davis AM, Gossing M, Hayes MA, Romero E, Scott LH, Wigglesworth MJ. A perspective on synthetic biology in drug discovery and development-current impact and future opportunities. SLAS Discov. 2021;26(5):581–603. DOI: 10.1177/24725552211000669

30. Robertson MJ, Meyerowitz JG, Skiniotis G. Drug discovery in the era of cryo-electron microscopy. Trends Biochem Sci. 2022;47(2):124–35. DOI: 10.1016/j.tibs.2021.06.008

31. Santos IC, Brodbelt JS. Recent developments in the characterization of nucleic acids by liquid chromatography, capillary electrophoresis, ion mobility, and mass spectrometry (2010-2020). J Sep Sci. 2021;44(1):340–72. DOI: 10.1002/jssc.202000833

32. Campuzano IDG, Sandoval W. Denaturing and Native Mass Spectrometric Analytics for Biotherapeutic Drug Discovery Research: Historical, Current, and Future Personal Perspectives. J Am Soc Mass Spectrom. 2021;32(8):1861–85. DOI: 10.1021/jasms.1c00036

33. Akkapeddi P, Teng KW, Koide S. Monobodies as tool biologics for accelerating target validation and druggable site discovery. RSC Med Chem. 2021;12(11):1839–53. DOI: 10.1039/d1md00188d

34. Sim DS, Kauser K. In vivo target validation using biological molecules in drug Development. Handb Exp Pharmacol. 2016;232:59–70. DOI: 10.1007/164_2015_17

35. Loewa A, Feng JJ, Hedtrich S. Human disease models in drug development. Nat Rev Bioeng. 2023:1–15. DOI: 10.1038/s44222-023-00063-3

36. Bull SC, Doig AJ. Properties of protein drug target classes. PLoS One. 2015;10(3):e0117955. DOI: 10.1371/journal.pone.0117955

37. Cheng L, Xia F, Li Z, Shen C, Yang Z, Hou H, Sun S, Feng Y, Yong X, Tian X, Qin H, Yan W, Shao Z. Structure, function and drug discovery of GPCR signaling. Mol Biomed. 2023;4(1):46. DOI: 10.1186/s43556-023-00156-w

38. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48. DOI: 10.1038/s41392-022-00904-4

39. Alejandra WP, Miriam Irene JP, Fabio Antonio GS, Patricia RR, Elizabeth TA, Aleman-Aguilar JP, Rebeca GV. Production of monoclonal antibodies for therapeutic purposes: A review. Int Immunopharmacol. 2023;120:110376. DOI: 10.1016/j.intimp.2023.110376

40. Bussiere JL. Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin Drug Metab Toxicol. 2008;4(7):871–7. DOI: 10.1517/17425255.4.7.871

41. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951. DOI: 10.3389/fimmu.2020.01951

42. Prior H, Haworth R, Labram B, Roberts R, Wolfreys A, Sewell F. Justification for species selection for pharmaceutical toxicity studies. Toxicol Res (Camb). 2020;9(6):758–70. DOI: 10.1093/toxres/tfaa081

43. Namdari R, Jones K, Chuang SS, Van Cruchten S, Dincer Z, Downes N, Mikkelsen LF, Harding J, Jäckel S, Jacobsen B, Kinyamu-Akunda J, Lortie A, Mhedhbi S, Mohr S, Schmitt MW, Prior H. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice. Regul Toxicol Pharmacol. 2021;126:105029. DOI: 10.1016/j.yrtph.2021.105029

44. Attarwala H. TGN1412: From Discovery to Disaster. J Young Pharm. 2010;2(3):332–6. DOI: 10.4103/0975-1483.66810

45. Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161(3):512–26. DOI: 10.1111/j.1476-5381.2010.00922.x

46. Weißmüller S, Kronhart S, Kreuz D, Schnierle B, Kalinke U, Kirberg J, Hanschmann KM, Waibler Z. TGN1412 induces lymphopenia and human cytokine release in a humanized mouse model. PLoS One. 2016;11(3):e0149093. DOI: 10.1371/journal.pone.0149093

47. Bhutani P, Joshi G, Raja N, Bachhav N, Rajanna PK, Bhutani H, Paul AT, Kumar R. U.S. FDA approved drugs from 2015-June 2020: A perspective. J Med Chem. 2021;64(5):2339–81. DOI: 10.1021/acs.jmedchem.0c01786

48. Brown BL, Mitra-Majumdar M, Joyce K, Ross M, Pham C, Darrow JJ, Avorn J, Kesselheim AS. Trends in the quality of evidence supporting FDA drug approvals: results from a literature review. J Health Polit Policy Law. 2022;47(6):649–672. DOI: 10.1215/03616878-10041093

49. Passi I, Salwan S, Kumar B. US-FDA approved drugs in 2020 and 2021: A review. Mini Rev Med Chem. 2023;23(12):1273–97. DOI: 10.2174/1389557523666221208104530

50. Al-Madhagi HA. FDA-approved drugs in 2022: A brief outline. Saudi Pharm J. 2023;31(3):401–9. DOI: 10.1016/j.jsps.2023.01.007